Lilly’s Jaypirca Reduces Risk of Disease Progression or Death by 45% in CLL/SLL
INDIANAPOLIS, Indiana, June 14, 2026 Eli Lilly and Company announced compelling results from the pivotal Phase 3 BRUIN CLL-322...
EHA 2026
Advertisement
FDA Clears Dexcom Stelo OTC CGM for Children
SILVER SPRING, Maryland, June 12, 2026 The U.S. Food and Drug Administration (FDA) has cleared the Dexcom Stelo Glucose...
Menarini Reports Positive Phase 3 SENTRY Data at EHA
FLORENCE, Italy and NEW YORK, June 14, 2026 Menarini Group and its oncology-focused subsidiary Stemline Therapeutics have announced promising...
Lyell Immunopharma Showcases Updated Ronde-Cel Data at EHA 2026
SOUTH SAN FRANCISCO, Calif., June 12, 2026 Lyell Immunopharma, Inc. announced updated safety and translational data for rondecabtagene autoleucel...
Agios Highlights RISE UP Phase 3 Results at EHA 2026
CAMBRIDGE, Mass., June 13, 2026 Agios Pharmaceuticals, Inc. announced detailed results from the 52-week double-blind portion of the global...
Advertisements
HUTCHMED Reports Positive Phase III Sovleplenib Results in wAIHA
Hong Kong, Shanghai & Florham Park, N.J., June 12, 2026 HUTCHMED (China) Limited announced positive results from the Phase...
Genmab Reports Positive EPCORE FL-1 Data for Epcoritamab Combination
COPENHAGEN, Denmark, June 11, 2026 Genmab A/S announced new subgroup analysis results from the pivotal Phase 3 EPCORE FL-1...
Johnson & Johnson’s IMAAVY Delivers Breakthrough Results in wAIHA
STOCKHOLM, Sweden, June 11, 2026 Johnson & Johnson has reported positive pivotal Phase 2/3 results for IMAAVY® (nipocalimab-aahu) in...
Enliven Therapeutics Reports Positive ELVN-001 Phase 1 Data
BURLINGAME, Calif., June 11, 2026 Enliven Therapeutics announced updated positive Phase 1 clinical data for ELVN-001, its investigational BCR::ABL1-targeted...
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Eti-cel Data at EHA 2026
NEW YORK, NY, June 11, 2026 Cellectis announced final Phase 1 results from the BALLI-01 clinical trial evaluating lasme-cel,...
Advertisement
